Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about GLP-1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | GLP-1 |
| Key Genes/Proteins | alpha-synuclein, Aβ, BDNF, GDNF, GLP-1 receptor |
| Related Diseases | Alzheimer's disease, Alzheimer's Disease |
| Related Pathways | Ca2+ deregulation, cognition, energy metabolism, ER stress, Insulin Signaling |
Knowledge base pages for this entity
graph TD
GLP_1[GLP-1]
GLP_1 -->|binds| GLP_1R[GLP-1R]
GLP_1 -->|promotes| Insulin_Signaling[Insulin Signaling]
GLP_1 -.protects against.-> synaptic_function[synaptic function]
GLP_1 -->|improves| cognition[cognition]
GLP_1 -->|improves| learning[learning]
GLP_1 -->|improves| motor_function[motor function]
GLP_1 -->|ameliorates| __synuclein[α-synuclein]
GLP_1 -->|suppresses| Ca2__deregulation[Ca2+ deregulation]
GLP_1 -->|suppresses| ER_stress[ER stress]
GLP_1 -->|enhances| neuronal_insulin_sensitivity[neuronal insulin sensitivity]
Tirzepatide[Tirzepatide] -->|activates| GLP_1| Target | Relation | Type | Str |
|---|---|---|---|
| GLP-1R | binds | receptor | 0.95 |
| Insulin Signaling | associated_with | pathway | 0.95 |
| synaptic function | protects_against | biological_process | 0.80 |
| cognition | improves | biological_process | 0.80 |
| learning | improves | biological_process | 0.80 |
| motor function | improves | biological_process | 0.80 |
| α-synuclein | ameliorates | protein | 0.80 |
| Ca2+ deregulation | suppresses | biological_process | 0.80 |
| ER stress | suppresses | biological_process | 0.80 |
| neuronal insulin sensitivity | enhances | biological_process | 0.80 |
| energy metabolism | enhances | biological_process | 0.80 |
| BDNF | upregulates | protein | 0.80 |
| GDNF | upregulates | protein | 0.80 |
| NEURODEGENERATION | treats | disease | 0.80 |
| Alzheimer's disease | protects_against | disease | 0.80 |
| Parkinson's disease | protects_against | disease | 0.80 |
| neurons | protects_against | cell_type | 0.80 |
| microglia | protects_against | cell_type | 0.80 |
| astrocytes | protects_against | cell_type | 0.80 |
| Aβ | ameliorates | protein | 0.80 |
| Tau | ameliorates | protein | 0.80 |
| alpha-synuclein | inhibits | protein | 0.70 |
| Alzheimer's Disease | protects_against | disease | 0.70 |
| mitochondrial function | regulates | process | 0.70 |
| PPARGC1A | regulates | protein | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Tirzepatide | activates | drug | 0.95 |
| GLP-1 receptor | binds | gene | 0.70 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Physiological SCFAs may confer indirect anti-synuclein benef | 0.670 | neurodegeneration | Do physiological concentrations of SCFAs |
| The most realistic translational use of physiological SCFAs | 0.610 | neurodegeneration | Do physiological concentrations of SCFAs |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.699
neurodegeneration | 2026-04-14 | 0 hypotheses
neurodegeneration | 2026-04-02 | 3 hypotheses Top: 0.652
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.95 · 2026-04-16
closed · Rounds: 4 · Score: 0.95 · 2026-04-15
closed · Rounds: 4 · Score: 0.73 · 2026-04-02
Hypotheses and analyses mentioning GLP-1 in their description or question text
No additional research found